Sun Pharma Q2FY21 results update

Last updated: 03 Nov, 2020 | 03:01 pm

Sun Pharma Q2FY21 results update

Sun Pharmaceutical Industries Ltd., Indian drug manufacturer, serving primarily India and the US markets, on Tuesday declared their quarterly results.

Profit: Coming out of a ₹ 1,656 crore loss from last quarter, Sun Pharma’s net profit soared 70% year-on-year to ₹ 1,813 crore for the quarter ending September 2020 backed by improved margins, reducing costs and tax credit. EBITDA grew 22.5% to ₹ 2,193.3 crore, with margin increasing 360bps year-on-year to 25.6%.

Revenue and Costs: Consolidated revenue from operations grew 5.3% year-on-year and 13% quarter-on-quarter to ₹ 8,553 crore. The expenses declined by 3% to ₹ 2,392 crore.

Tax Credit and Forex Loss: Tax credit of ₹ 288 crore was on account of creation of deferred tax asset as attributable to restructuring of an acquired entity, aiding the overall profit. Forex loss of ₹ 116.4 crore was reported against ₹ 8.5 crore gain in the same period last year. 

US Subsidiary: Taro Pharmaceutical Industries Ltd., Sun Pharma’s US subsidiary saw a decline in sales of 25.7% year-on-year. The US business adds to nearly 30% of Sun Pharma’s sales at a consolidated level.

Important Ratios:

Debt-to-equity ratio was down 0.13 from 0.18 last quarter. This ratio measures the financing used to run operations, a lower ratio and a decreasing one as in this case, shows the company has more owned capital than borrowed, and this shows about the growing strengths of the company.

Debt service coverage ratio: This ratio measures the operating profit available to the company, to service its all debt payment related obligations. The ratio was at 1.02 for quarter ending September 2020, a marginal decrease quarter-on-quarter.

Interest Service Coverage Ratio: Unlike debt service, this ratio includes only the financing costs which are supposed to be covered by companies’ EBIT (Earnings before interest and tax). The ratio increased two-fold to 40.5 from last quarter, implying solid interest repayment capability.

Capital Raising: Sun Pharma has issued ₹ 900 crore worth of unsecured commercial papers during the quarter, with ₹ 500 crore repayable in December 2020 and ₹ 400 crore repayable in Q1FY22.

Sun Pharma ended day’s trade at 485.6, up 3.45% from yesterday. Sun pharma continues to monitor the impact of Covid-19 on its business, customers, supply-chain, employees, and logistics. The rebound in profit shows Sun Pharma’s standing as a large drugmaker and recovery in sales.

Finzoom Investment Advisors Private Limited (Brand Name - INDmoney, INDwealth,,, makes no warranties or representations, express or implied, on products and services offered through the platform. It accepts no liability for any damages or losses, however, caused in connection with the use of, or on the reliance of its advisory or related services.

Past performance is not indicative of future returns. Please consider your specific investment requirements, risk tolerance, goal, time frame, risk and reward balance and the cost associated with the investment before choosing a fund, or designing a portfolio that suits your needs. Performance and returns of any investment portfolio can neither be predicted nor guaranteed.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Marketing and distribution of various financial products such as loans and deposits are powered by Finzoomers Services Private Limited.

INDmoney, INDwealth, are brand and product of Finzoom Investment Advisors (P) Limited.

© Finzoom Investment Advisors Private Limited

[SEBI RIA Registration No: INA100012190] [Type of Registration: Non-Individual] [Validity of registration: December 17, 2018-Perpetual] [Address: 616, 6th Floor, Suncity Success Tower, Golf Course Extension Road, Sector – 65, Gurugram, Haryana- 122005] [Principal Officer details: Mr. Gaurav Sharma, Email id:, Contact No. 8800826254] [Corresponding SEBI local office address: Securities and Exchange Board of India, Local Office, First Floor, SCO 127-128, Sector 17C, Chandigarh-160017]

[ARN - 151913] [Platform Partner : BSE (Member code-24801)] [CIN - U67190HR2018PTC073294] [GST No : 06AADCF3538Q1Z8]